TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02370745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLP-1
Description: GLP-1 effects on skeletal muscle glucose and amino acid metabolism and microvascular blood flow will be scrutinised under the specified insulin concentrations. It will also be used to test the effect of intravenous feed on insulin secretion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLP-1
Description: GLP-1 effects on skeletal muscle glucose and amino acid metabolism and microvascular blood flow will be scrutinised under the specified insulin concentrations. It will also be used to test the effect of intravenous feed on insulin secretion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Actrapid
Description: Skeletal muscle metabolic and microvascular parameters will be tested under specified insulin concentrations with or without GLP-1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Actrapid
Description: Skeletal muscle metabolic and microvascular parameters will be tested under specified insulin concentrations with or without GLP-1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Actrapid
Description: Skeletal muscle metabolic and microvascular parameters will be tested under specified insulin concentrations with or without GLP-1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Actrapid
Description: Skeletal muscle metabolic and microvascular parameters will be tested under specified insulin concentrations with or without GLP-1

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral amino acids
Description: Oral amino acids containing 15 g of amino acids

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral amino acids
Description: Oral amino acids containing 15 g of amino acids
Study: NCT03442881

Intervention type: PROCEDURE
Intervention: Excision of adnexal mass through laprotomy
Description: Through laparotomy incision, the adnexal mass will be excised

Intervention type: PROCEDURE
Intervention: Excision of adnexal mass through laprotomy
Description: Through laparotomy incision, the adnexal mass will be excised
Study: NCT02804555

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen
Description: Oxygen administration
Study: NCT00918463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib
Description: 100 mg daily dosing
Study: NCT00963079

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Embryo cryopreservation
Description: Cohort cryopreserved as bipronuclear (2pn) oocytes, then thawed and cultured to the blastocyst stage before transfer to the uterus.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fresh blastocyst transfer
Description: Fresh blastocyst transfer following cycle of controlled ovarian stimulation.
Study: NCT04259385

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exposure to beverage calorie information
Description: Calories for sugar-sweetened and non-sugar-sweetened beverages

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure to beverage calorie information
Description: Calories for sugar-sweetened and non-sugar-sweetened beverages

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure to beverage calorie information
Description: Calories for sugar-sweetened and non-sugar-sweetened beverages
Study: NCT01630096

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nu-Lytely
Description: Bowl prep solution.
Study: NCT02277704

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TNX-102 SL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TNX-102 SL

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study: NCT01847443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine (2 mg)
Description: 2 mg nicotine gum in two formulations

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine (4 mg)
Description: 4 mg nicotine gum in two formulations

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine (4 mg)
Description: 4 mg nicotine gum in two formulations
Study: NCT03062943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Study: NCT04052373

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implantoplasty
Description: Implantoplasty is the mechanical smoothening of rough titanium implants as part of the surgical treatment of peri-implantitis. Treatment is thought to facilitate self-performed oral hygiene.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Implantoplasty
Description: Implantoplasty is the mechanical smoothening of rough titanium implants as part of the surgical treatment of peri-implantitis. Treatment is thought to facilitate self-performed oral hygiene.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open flap debridement alone
Description: Open flap debridement alone

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open flap debridement alone
Description: Open flap debridement alone
Study: NCT02321228

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Salpingectomy with delayed oophorectomy
Description: Early salpingectomy upon completions of childbearing with postponement of oophorectomy until between 40 and 45 in BRCA1 mutation carriers and between age 45 and 50 in BRCA2 mutation carriers.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Risk-reducing salpingo-oophorectomy
Description: This is the current guideline procedure, usually performed between age 35 and 40 in BRCA1 mutation carriers and between age 40 and 45 in BRCA2 mutation carriers.
Study: NCT03596619

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PBN
Description: The PBN-ALA-PDT group underwent vertical skin tapping with PBN before applying 10% ALA cream and narrow-band light-emitting diode (LED) irradiation (mean 633 nm, with a standard deviation \[SD\] of 10 nm; 100-200 J/cm2). The ALA-PDT group received ALA cream and irradiation only.
Study: NCT02675153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin
Description: Participants with gastrointestinal strictures were treated with rapamycin 2mg daily at least six months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin
Description: Participants with gastrointestinal strictures were treated with rapamycin 2mg daily at least six months.
Study: NCT01769261

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eligible, Internet
Description: Patients randomized in the internet arm. They will directly complete their health evolution after hospital discharge via the internet.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: eligibles, telephone
Description: Patients randomized in the telephone arm. Their health evolution after hospital discharge will be documented via a telephone interview at J45 after hospital discharge

Intervention type: OTHER
Group type: OTHER
Intervention: non eligibles
Description: Patients who do not have an internet access at home. Their health evolution after hospital discharge will be documented via a telephone interview at J45. after hospital discharge.
Study: NCT00501046

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 9g /day (3 times a day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AST-120
Description: 9g /day (3 times a day)
Study: NCT00393913

Intervention type: DEVICE
Intervention: Continuous Positive Airway Pressure (CPAP)
Description: Positive airway pressure delivered via a nasal mask titrated to a therapeutic level to eliminate all sleep disordered breathing to be used every night for 4-6 weeks.
Study: NCT03767296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ephedrine Hydrochloride 3 MG/ML
Description: Bolus group, according to the randomization. Multiple boluses with incremental doses might be needed, according to the MAP ('effect titration')~Incremental doses if needed:~Ephedrine (E): 6 mg, 6mg, 9 mg, 9 mg, 12 mg, .....(max 24mg/bolus) A total amount of 140 mg Ephedrine will not be exceeded.~Titrated according to the desired effect (= MAP decrease \< 20%)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ephedrine Hydrochloride 3 MG/ML
Description: Bolus group, according to the randomization. Multiple boluses with incremental doses might be needed, according to the MAP ('effect titration')~Incremental doses if needed:~Ephedrine (E): 6 mg, 6mg, 9 mg, 9 mg, 12 mg, .....(max 24mg/bolus) A total amount of 140 mg Ephedrine will not be exceeded.~Titrated according to the desired effect (= MAP decrease \< 20%)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ephedrine Hydrochloride 3 MG/ML
Description: Bolus group, according to the randomization. Multiple boluses with incremental doses might be needed, according to the MAP ('effect titration')~Incremental doses if needed:~Ephedrine (E): 6 mg, 6mg, 9 mg, 9 mg, 12 mg, .....(max 24mg/bolus) A total amount of 140 mg Ephedrine will not be exceeded.~Titrated according to the desired effect (= MAP decrease \< 20%)
Study: NCT02370745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GIP
Description: This will be co infused with GLP-1 and intravenous amino acids

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous amino acids
Description: This will aim to deliver iso equivalent amount to the amino acids administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous amino acids
Description: This will aim to deliver iso equivalent amount to the amino acids administered orally
Study: NCT02072083

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: via intranasal route 1 mcg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: via intranasal route 7,5 mg/kg ketamine and 0,1 mg/kg midazolam
Study: NCT01885403

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: non-invasive respiratory parameter measurements
Study: NCT04424888

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WB-011
Description: WB-011 medical food product.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Capsules identical to those containing WB-011.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Continuous Glucose Monitor
Description: Abbott Freestyle Libre(™) Glucose Sensors were used throughout the study.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitor
Description: Abbott Freestyle Libre(™) Glucose Sensors were used throughout the study.
Study: NCT03767296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: Bolus group, according to the randomization. Multiple boluses with incremental doses might be needed, according to the MAP ('effect titration')~Incremental doses if needed:~Phenylephrine (PE): 50μg, 50μg, 100μg, 100μg, 150μg, 150μg,...(max 500µg/bolus) A total amount of 1500 μg will not be exceeded. Titrated according to the desired effect (= MAP decrease \< 20%)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: Bolus group, according to the randomization. Multiple boluses with incremental doses might be needed, according to the MAP ('effect titration')~Incremental doses if needed:~Phenylephrine (PE): 50μg, 50μg, 100μg, 100μg, 150μg, 150μg,...(max 500µg/bolus) A total amount of 1500 μg will not be exceeded. Titrated according to the desired effect (= MAP decrease \< 20%)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: Bolus group, according to the randomization. Multiple boluses with incremental doses might be needed, according to the MAP ('effect titration')~Incremental doses if needed:~Phenylephrine (PE): 50μg, 50μg, 100μg, 100μg, 150μg, 150μg,...(max 500µg/bolus) A total amount of 1500 μg will not be exceeded. Titrated according to the desired effect (= MAP decrease \< 20%)
Study: NCT01850862

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collective group exercise program in patients with KOA

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Orientation (without exercise)
Description: Orientation about osteoarthritis disease but without any exercise program
Study: NCT04627142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1701963
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1701963
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camptosar®
Description: Solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camptosar®
Description: Solution for infusion
Study: NCT03298191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: Those women will be given Magnesium Sulfate for tocolysis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritodrine
Description: Those women will be given Ritodrine for tocolysis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Channel Blockers
Description: Those women will be given Calcium Channel Blockers for tocolysis
Study: NCT01011608

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Food Supplement
Description: Medical Food Supplement to be given in divided portions in morning, afternoon and evening

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard hospital food
Description: standard hospital diet ad. lib.
Study: NCT02510456

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diffuse Optical Spectroscopy Imaging (DOSI) - Neoadjuvant Chemo (NAC) Cohort
Description: Subjects will have up to 9 DOSI scans at 6 different time points during the course of their neoadjuvant chemotherapy. The time course of chemotherapy may vary between 3-9 months depending on the type chemotherapy subjects receive. Depending on chemotherapy schedule, subjects may or may not be asked to participate in all the 6 measurement time points. The number of DOSI scans each subject requires will be decided during consent. Each DOSI scan will take about 30-60 minutes, although scans at infusion time point will take longer in total due to repeated or continuous measurements.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diffuse Optical Spectroscopy Imaging (DOSI) - Non-NAC Cohort
Description: Subjects will have 1 DOSI scan at baseline. The DOSI scan will take about 30-60 minutes.
Study: NCT04045717

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypo-FLAME 2.0 study
Description: SBRT technique with 35 Gy in 5 fractions to the whole prostate gland and an additional simultaneously integrated focal boost to the tumor nodule(s) visible on MRI up to 50 Gy (overall treatment time (OTT) = 15 days).
Study: NCT05579912

Intervention type: PROCEDURE
Intervention: Esophageal and gastric resections requiring an anastomosis
Description: Distal gastrectomies, total gastrectomies, bariatric gastric bypasses, subtotal esophagectomies, proximal gastrectomies, palliative bypasses, and total esophagectomies.
Study: NCT02325817

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug-eluting balloon
Description: Treat the side branch of bifurcation lesion with drug-eluting balloon

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Uncoated ballloon
Description: Treat the side branch of bifurcation lesion with uncoated balloon
Study: NCT04300491

Intervention type: OTHER
Intervention: Suspension walking training
Description: Physiotherapy session, objective wlaking with body weight support using a specific device
Study: NCT00259740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DENOSUMAB
Description: 120 mg administered subcutaneously on study days 1, 8, 15, and 29 and every 28 days thereafter. Each dose will be administered in two separate injections of 60 mg (1.0 mL) each.
Study: NCT03360357

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Guided drills
Description: These residents will perform 5 set of exercises:~1. Needle Dance (Learning to manipulate the suture)~2. Loopy Loop (Learning to place needle through a loop)~3. Slalom Course (Passing the needle and suture through 5 rings right handed and left handed)~4. Dense Matter (Passing the needle through dense material without losing control of the needle)~5. Respect for tissue (Passing the needle through flimsy material without tearing)
Study: NCT03252327

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multiple Sensory Integrations
Description: breast milk odor, oral expressed breast milk, heartbeat sounds, nonnutritive sucking.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multiple Sensory Integrations
Description: breast milk odor, oral expressed breast milk, heartbeat sounds, nonnutritive sucking.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multiple Sensory Integrations
Description: breast milk odor, oral expressed breast milk, heartbeat sounds, nonnutritive sucking.
Study: NCT04332016

Intervention type: OTHER
Intervention: biological samples collection
Description: collection of whole blood samples, urine and stool samples, upper respiratory samples, post-mortem biopsies
Study: NCT00896324

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Rehabilitation
Description: The cognitive rehabilitation procedure will involve a curriculum of game-like cognitive exercises designed to facilitate graded practice of EF skills including attention, processing speed, mental flexibility, planning and logic. The exercises will be delivered to participants via a secure, password protected website created specifically for this study by the PI. Subjects will complete a curriculum of cognitive exercises 30 minutes per day, 5 days per week for 6-weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Neurofeedback Training
Description: Neurofeedback training is a type of biofeedback during which the subjects will be trained to improve cognitive function by implementing certain cognitive strategies while receiving feedback of their own brain activity. This is done using an infrared spectroscopy (NIRS) system. NIRS measurements will be performed using an ETG-4000 NIRS system (Hitachi Medical, Tokyo, Japan), at two wavelengths of near-infrared light (695 and 830 nm). Each participant will have 2 or 3 sessions, each lasting approximately 30 minutes.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Neurofeedback Training (placebo / Sham)
Description: Neurofeedback training: 2-3, 30 min training sessions. For the sham placebo group, fabricated real-time data will be provided to the subject as feedback information hence enabling the subject to view information identical to experimental subjects but without accurate data pertaining to their own brain activation. The technician will be blinded to the subject's treatment condition assignment.
Study: NCT00217269

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coronary Artery Stenting
Description: Endeavor Drug eluting stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary Artery Stenting
Description: Taxus Drug Eluting Stent
Study: NCT03737318

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biofeedback-ultrasound
Description: In ultrasound biofeedback, the elements of traditional treatment (auditory models and verbal descriptions of articulator placement) are enhanced with a real-time ultrasound display of the shape and movements of the tongue. One or two target tongue shapes will be selected for each participant, and a trace of the selected target will be superimposed over the ultrasound screen. Participants will be cued to reshape the tongue to match this target during /r/ production.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biofeedback--visual-acoustic
Description: In visual-acoustic biofeedback treatment, the elements of traditional treatment (auditory models and verbal descriptions of articulator placement) are enhanced with a dynamic display of the speech signal in the form of the real-time LPC (Linear Predictive Coding) spectrum. Because correct vs incorrect productions of /r/ contrast acoustically in the frequency of the third formant (F3), participants will be cued to make their real-time LPC spectrum match a visual target characterized by a low F3 frequency. They will be encouraged to attend to the visual display while adjusting the placement of their articulators and observing how those adjustments impact F3.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Traditional articulation treatment
Description: Traditional articulation treatment involves providing auditory models and verbal descriptions of correct articulator placement, then cueing repetitive motor practice. Images and diagrams of the vocal tract will be used as visual aids; however, no real-time visual display of articulatory or acoustic information will be made available.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Traditional articulation treatment
Description: Traditional articulation treatment involves providing auditory models and verbal descriptions of correct articulator placement, then cueing repetitive motor practice. Images and diagrams of the vocal tract will be used as visual aids; however, no real-time visual display of articulatory or acoustic information will be made available.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Traditional articulation treatment
Description: Traditional articulation treatment involves providing auditory models and verbal descriptions of correct articulator placement, then cueing repetitive motor practice. Images and diagrams of the vocal tract will be used as visual aids; however, no real-time visual display of articulatory or acoustic information will be made available.
Study: NCT01838928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Study: NCT00290251

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ulipristal acetate 20 mg
Description: ulipristal acetate at a daily dose of 20 mg, given once daily for three menstrual cycles or 90 - 102 days if amenorrheic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ulipristal acetate 10 mg
Description: 10 mg given daily for three menstrual cycles or 90 - 102 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo given once daily for 3 menstrual cycles or 90 - 102 days
Study: NCT03605251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS5315 low dose
Description: Oral administration for 12 or 36 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS5315 high dose
Description: Oral administration for 12 or 36 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Oral administration for 12 weeks (At Week 12, participants in the placebo group will be assigned to TAS5315 low or high dose group)
Study: NCT03874494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Description: Brexpiprazole 2-4 mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: Aripiprazole 10-20 mg/day
Study: NCT03653494

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: phrenic block
Description: phrenic block by 1% ropivacaine 5ml

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: no phrenic block
Description: no phrenic block